Home > Empagliflozin significantly reduces CV and renal risk

Empagliflozin significantly reduces CV and renal risk

Presented By
Dr Milton Packer, Baylor University Medical Center, Dallas, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EASD 2020
Trial
EMPEROR-Reduced
Data from the EMPEROR-Reduced trial (NCT03057977) showed that empagliflozin reduces the risk of cardiovascular (CV) death or hospitalisation for heart failure (HF) in patients with HF and a reduced ejection fraction (HFrEF).  This trial was designed to evaluate the effects of 10 mg empagliflozin once daily compared with placebo in patients with HFreEF, with or without diabetes, who were receiving treatment for HF [1,2]. The primary endpoint was the composite of CV death or hospitalisation for HF. The first secondary endpoint was total (first and recurrent) HF hospitalisation and the second secondary endpoint was the slope of decline in glomerular filtration rate (GFR) over time. A total of 3,730 patients with HF and a left ventricular ejection fraction of 40% or less, with or without diabetes, were randomised t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on